ALPHA COGNITION INC (ACOG) Stock Price, Quote, News and Overview
NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD
ACOG Quote, Performance and Key Statistics
NASDAQ:ACOG (8/5/2025, 1:05:55 PM)
8.8
+0.06 (+0.69%)
The current stock price of ACOG is 8.8 USD. In the past month the price decreased by -22.24%.
ACOG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.7 | 349.79B | ||
| AMGN | AMGEN INC | 14.46 | 161.39B | ||
| GILD | GILEAD SCIENCES INC | 14.64 | 140.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.04 | 100.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.59 | 62.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 54.18B | ||
| ARGX | ARGENX SE - ADR | 74.41 | 42.21B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.91 | 33.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.68B | ||
| INSM | INSMED INC | N/A | 21.29B | ||
| BIIB | BIOGEN INC | 8.33 | 19.55B |
Related stock screener links
About ACOG
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
Company Info
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 52
Phone: 16045649244
ALPHA COGNITION INC / ACOG FAQ
What is the stock price of ALPHA COGNITION INC today?
The current stock price of ACOG is 8.8 USD. The price increased by 0.69% in the last trading session.
What is the ticker symbol for ALPHA COGNITION INC stock?
The exchange symbol of ALPHA COGNITION INC is ACOG and it is listed on the Nasdaq exchange.
On which exchange is ACOG stock listed?
ACOG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALPHA COGNITION INC stock?
7 analysts have analysed ACOG and the average price target is 20.4 USD. This implies a price increase of 131.82% is expected in the next year compared to the current price of 8.8. Check the ALPHA COGNITION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALPHA COGNITION INC worth?
ALPHA COGNITION INC (ACOG) has a market capitalization of 140.98M USD. This makes ACOG a Micro Cap stock.
How many employees does ALPHA COGNITION INC have?
ALPHA COGNITION INC (ACOG) currently has 52 employees.
What are the support and resistance levels for ALPHA COGNITION INC (ACOG) stock?
ALPHA COGNITION INC (ACOG) has a support level at 8.73 and a resistance level at 9.99. Check the full technical report for a detailed analysis of ACOG support and resistance levels.
Should I buy ALPHA COGNITION INC (ACOG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACOG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACOG, evaluating the profitability, health, valuation and growth aspects
- ALPHA COGNITION INC (ACOG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALPHA COGNITION INC (ACOG) Sales and EPS estimates to see what analysts future expectations are.
- ALPHA COGNITION INC (ACOG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALPHA COGNITION INC (ACOG) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALPHA COGNITION INC (ACOG) Stock Chart to make your own analysis
- ALPHA COGNITION INC (ACOG) Latest news and press-releases to stay up to date.
Does ALPHA COGNITION INC (ACOG) stock pay dividends?
ACOG does not pay a dividend.
When does ALPHA COGNITION INC (ACOG) report earnings?
ALPHA COGNITION INC (ACOG) will report earnings on 2025-08-20.
What is the Price/Earnings (PE) ratio of ALPHA COGNITION INC (ACOG)?
ALPHA COGNITION INC (ACOG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is the Short Interest ratio of ALPHA COGNITION INC (ACOG) stock?
The outstanding short interest for ALPHA COGNITION INC (ACOG) is 0.73% of its float. Check the ownership tab for more information on the ACOG short interest.
ACOG Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ACOG.
ACOG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. ACOG has a great financial health rating, but its profitability evaluates not so good.
ACOG Financial Highlights
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 42.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.95% | ||
| ROE | -28.52% | ||
| Debt/Equity | 0 |
ACOG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACOG. The Buy consensus is the average rating of analysts ratings from 7 analysts.